Zacks.com on MSN

TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia

Teva files an NDA seeking FDA approval for its once-monthly olanzapine LAI for the treatment of adults with schizophrenia.

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a ...
PsyPost on MSN

Semaglutide helps manage metabolic side effects of antipsychotic drugs

Recent clinical research indicates that semaglutide may effectively reverse weight gain and blood sugar issues caused by ...
News.az

Ozempic may cut health risks in Schizophrenia patients

People with schizophrenia often take strong antipsychotics that control symptoms but frequently cause rapid weight gain, high blood sugar, and a ...
Zacks Investment Research on MSN

Teva stock trading above 200- & 50-day SMA for 2 months: How to play

Teva Pharmaceutical Industries Limited’s TEVA stock has been trading above its 50-day and 200-day simple moving averages ...

Schizophrenia Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, …

In April 2025, CMG Pharmaceutical, a subsidiary of CHA Biotech, secured FDA approval for Mezofy (formerly Depipzo), an oral ...
Medical Dialogues

Semaglutide Patent Clash: Delhi HC Denies Novo Nordisk Injunction, Manufacturing by Dr Reddy's to Continue

In a significant development in the high-stakes patent litigation over diabetes blockbuster Semaglutide, the Delhi High Court has refused to grant Danish innovator Novo Nordisk ...